Aclaris Therapeutics (ACRS) Non Operating Income (2015 - 2026)

Aclaris Therapeutics' Non Operating Income history runs 6 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 21.04% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $10.8 million (changed 0.5% YoY), while the FY2025 annual figure was $11.5 million, up 16.06% from the prior year.
• Non Operating Income for Q1 2026 stood at $2.4 million, down from $2.9 million in the prior quarter.
• The five-year high for Non Operating Income was $3.1 million in Q4 2024, with the low at $1.9 million in Q2 2024.
• The 4-year median for Non Operating Income is $2.5 million (2025), against an average of $2.6 million.
• The sharpest annual moves came in 2025 and 2026: Non Operating Income jumped 59.48% in 2025, then declined 21.04% in 2026.
• Aclaris Therapeutics' Non Operating Income stood at $2.2 million in 2023, then surged by 42.67% to $3.1 million in 2024, then decreased by 5.89% to $2.9 million in 2025, then decreased by 19.43% to $2.4 million in 2026.
• Business Quant data shows ACRS's Non Operating Income at $2.4 million in Q1 2026, $2.9 million in Q4 2025, and $2.5 million in Q3 2025.